Clinical Pros of Sacituzumab and T-DXd

Panelists discuss how sacituzumab shows significant efficacy in triple-negative breast cancer, with improved progression-free and overall survival. It demonstrates particular benefit in pretreated patients and brain metastases cases. Trastuzumab deruxtecan (T-DXd) excels in HER2-positive breast cancer treatment, showing remarkable response rates and survival benefits, including in patients with brain metastases and those who progressed on prior therapies.